title: Retrospective analysis of prognosticators in patients with relapsed Hodgkin's Lymphoma treated with autologous transplant: results of a single center.
abstract: Hodgkin's Lymphoma (HL) is highly chemoresponsive, and majority of patients respond to therapy except for a small number which require high-dose therapy and stem cell rescue for salvage. We report the results of a single-center experience in 41 patients with relapsed HL treated with high-dose therapy at the time of relapse from the year 1989-2010. The 7-year OS for the group is 39.2 %; the median progression-free survival is 30.6 months. Univariate analysis identified refractory disease at transplant and extranodal involvement as important prognosticators. The 100-day mortality was 5 %. The most common cause for delayed mortality was disease progression. The incidence of secondary malignancy in the group was 2 %. Our results reinforce the significance of long-term follow up as late relapses are observed. Additionally, identifying biological prognosticators and implying them for treatment may improve the outcomes in poor-risk patients.
authors.affiliation: Department of Bone Marrow Transplant, The Tisch Cancer Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY, USA. amasood461@gmail.com
authors.forename: Aisha
authors.initials: A
authors.lastname: Masood
authors.forename: Amir
authors.initials: A
authors.lastname: Steinberg
authors.forename: Erin
authors.initials: E
authors.lastname: Moshier
authors.forename: Adriana
authors.initials: A
authors.lastname: Malone
authors.forename: Eileen
authors.initials: E
authors.lastname: Scigliano
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Nieto
authors.forename: Keren
authors.initials: K
authors.lastname: Osman
authors.forename: Celia
authors.initials: C
authors.lastname: Grosskreutz
authors.forename: Luis
authors.initials: L
authors.lastname: Isola
authors.forename: Joshua
authors.initials: J
authors.lastname: Brody
mesh_terms: D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000401:mortality* / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D014182:Transplantation, Autologous; D055815:Young Adult